U.S. patent application number 10/769288 was filed with the patent office on 2005-05-26 for probe/mobility modifier complexes for multiplex nucleic acid detection.
This patent application is currently assigned to Applera Corporation. Invention is credited to Grossman, Paul D..
Application Number | 20050112594 10/769288 |
Document ID | / |
Family ID | 22414554 |
Filed Date | 2005-05-26 |
United States Patent
Application |
20050112594 |
Kind Code |
A1 |
Grossman, Paul D. |
May 26, 2005 |
Probe/mobility modifier complexes for multiplex nucleic acid
detection
Abstract
Compositions and methods for the analysis of multiple nucleic
acid target sequences are disclosed. The compositions comprise a
probe comprising a target-specific portion for sequence-specific
hybridization to a target nucleic acid sequence, and a tag; and a
mobility-modifier comprising a tail and a tag complement for
binding to the tag. The associated methods generally comprise the
steps of providing a sample potentially containing one or more
target nucleic acid sequences; providing one or more probes, each
probe comprising a target-specific portion and a tag; providing one
or more mobility modifiers, each mobility modifier comprising a tag
complement and a tail; contacting the probe(s) and the target
nucleic acid sequence(s) under conditions effective for
sequence-dependent hybridization of the probe(s) and the target
nucleic acid sequence(s); contacting the probe(s) and the
mobility-modifier(s) under conditions suitable for selectively
binding the probe(s) to the mobility modifier(s), thereby forming
one or more a probe/mobility modifier complex(s); and analyzing the
probe/mobility modifier complex(s) using a mobility-dependent
analysis technique.
Inventors: |
Grossman, Paul D.;
(Hillsborough, CA) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON
DC
20001-4413
US
|
Assignee: |
Applera Corporation
|
Family ID: |
22414554 |
Appl. No.: |
10/769288 |
Filed: |
January 29, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10769288 |
Jan 29, 2004 |
|
|
|
09724730 |
Nov 28, 2000 |
|
|
|
6734296 |
|
|
|
|
09724730 |
Nov 28, 2000 |
|
|
|
09522640 |
Mar 10, 2000 |
|
|
|
6395486 |
|
|
|
|
60124386 |
Mar 15, 1999 |
|
|
|
Current U.S.
Class: |
435/6.16 ;
530/350; 536/24.3 |
Current CPC
Class: |
C12Q 1/6858 20130101;
C12Q 1/6834 20130101; C12Q 1/6827 20130101; C12Q 2563/179 20130101;
C12Q 2537/143 20130101; C12Q 2535/125 20130101; C12Q 2563/179
20130101; C12Q 2525/161 20130101; C12Q 2537/143 20130101; C12Q
1/6813 20130101; C12Q 1/6827 20130101; C12Q 1/6858 20130101 |
Class at
Publication: |
435/006 ;
536/024.3; 530/350 |
International
Class: |
C12Q 001/68; C07H
021/04; C07K 014/00 |
Claims
1. A binary composition for detecting one or more target nucleic
acid sequences comprising: a probe comprising a target-specific
portion for sequence-specific hybridization to a target nucleic
acid sequence, and a tag; and a mobility-modifier comprising a tail
and a tag complement for binding to the tag.
2. The composition of claim 1 wherein the target-specific portion
comprises polynucleotide.
3. The composition of claim 2 wherein the target-specific portion
comprises a 3'-hydroxyl group.
4. The composition of claim 2 wherein the target-specific portion
comprises PNA.
5. The composition of claim 1 wherein the tag portion comprises
polynucleotide.
6. The composition of claim 5 wherein the tag portion is PNA.
6.1 (canceled)
7. The composition of claim 1 wherein both the tag and tag
complement are polynucleotide, and one of the tag complement and
tag comprises a sequence selected from the group consisting of
(CAG).sub.n and (TCC).sub.n wherein n is 1 to 10.
8. The composition of claim 1 wherein the mobility modifier
comprises a tail portion.
9. The composition of claim 8 wherein the tail is a polymer.
10. The composition of claim 9 wherein the polymer is selected from
the group consisting of polyethyleneoxide and polypeptide.
11. The composition of claim 1 further comprising a hybridization
enhancer.
12-25. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of application Ser. No.
09/522,640 filed Mar. 10, 2000, which claims the benefit of
provisional application Ser. No. 60/124,386 filed Mar. 15,
1999.
FIELD OF THE INVENTION
[0002] This invention relates to methods and compositions useful
for the analysis of nucleic acid sequences. In particular, the
invention provides methods and compositions useful for the analysis
of mixtures of multiple nucleic acid sequences.
BACKGROUND
[0003] Nucleic acid analysis techniques capable of large-scale
multiplex analysis of a plurality of polymorphic loci are needed
for a variety of practically important applications, e.g., for the
identification of individuals, e.g., paternity testing or in
forensic analysis, for organ transplant donor-recipient matching,
for genetic disease diagnosis, prognosis and genetic counseling,
for characterization of infectious agents, and for the study of
oncogenic mutations. Many of these applications depend on the
ability to discriminate single-nucleotide differences in a target
nucleic acid sequence at a multiplicity of loci.
[0004] One solution to the problem of multiplex analysis of nucleic
acids is to use arrays of different-sequence nucleic acids attached
to a solid support, where the sequence of the attached nucleic
acids are related to their location in the array (e.g., Kucherlapti
and Childs, Nature Genetics, 21: 15-19 (1999); Lipshutz et al.,
Nature Genetics, 21: 20-24 (1999)). However, nucleic acid arrays
have several significant practical drawbacks including (1) issues
associated with the fabrication of arrays, e.g., the expense and
complexity of the fabrication and testing of arrays, e.g., by in
situ synthesis or spotting; (2) characterization of arrays once
they are fabricated, e.g., confirmation that the proper sequence is
located at the proper location; (3) the integrity the nucleic acid
at each array location, e.g., there may be intra-strand
cross-linking and/or multiple constraining contacts between the
solid support and the bound nucleic acid; and (4) difficulties
associated with detecting hybridization events on a solid support,
e.g., fluorescence background and/or non-specific binding of a
labeled entity to the support.
[0005] In an alternative approach, multiple probes are analyzed by
electrophoretically separating probes that include
mobility-modifying tails that correlate a particular probe with a
particular mobility address (e.g., Grossman et al., Nucl. Acids
Res., 22: 4527-4534 (1994); Grossman et al., U.S. Pat. No.
5,624,800). However, this approach has the drawback of requiring
the synthesis of a large number of tailed probes.
[0006] Thus, there remains a continuing need for a nucleic acid
analysis technique that permits highly multiplexed analysis without
the drawbacks associated with nucleic acid arrays or with existing
mobility-based methods.
SUMMARY
[0007] The present invention is directed towards methods and
compositions useful for the multiplex analysis of nucleic
acids.
[0008] In a first aspect, the present invention provides a binary
composition for detecting one or more target nucleic acid sequences
in a mixture. The binary composition includes a probe having a
target-specific portion for sequence-specific hybridization to a
target nucleic acid sequence, and a tag. The binary composition
further includes a mobility modifier having a tail and a tag
complement for binding to the tag. When the probe and the mobility
modifier are bound through the tag and tag complement, a
probe/mobility modifier complex is formed. In a preferred
embodiment, the probe comprises a polynucleotide.
[0009] In a second aspect, the present invention provides a method
for detecting one or more target nucleic acid sequences present in
a sample. In the method, a sample potentially containing one or
more target nucleic acid sequences is contacted with one or more
probes under conditions effective for sequence-dependent
hybridization of the probe and the target nucleic acid sequence,
where each probe includes a target-specific portion and a tag.
Next, the hybridized probe is treated to form a modified probe,
where the treatment is effective to distinguish probes that have
bound to the target nucleic acid from those that have not. Before
or after the probes are contacted with the target nucleic acid, the
probe are contacted with one or more mobility-modifiers to form a
probe/mobility modifier complex, each mobility modifier having a
tag complement for binding selectively to the tag of an associated
probe, and a tail. Finally, the probe/mobility modifier complex is
analyzed using a mobility-dependent analysis technique.
[0010] The present invention will become better understood with
reference to the following written description, drawings, and
appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1 shows a schematic representation of a probe according
to the present invention.
[0012] FIG. 2 shows a schematic representation of a mobility
modifier according to the present invention.
[0013] FIG. 3 shows a schematic representation of a probe/mobility
modifier complex of the present invention.
[0014] FIGS. 4A, 4B, 4C and 4D show various stages of a schematic
representation of a preferred method according to the present
invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Reference will now be made in detail to the preferred
embodiments of the present invention, examples of which are
illustrated in the accompanying drawings. While the invention will
be described in conjunction with these preferred embodiments, it
will be understood that the invention is not intended to be limited
to those embodiments. On the contrary, the invention is intended to
cover alternatives, modifications, and equivalents of these
preferred embodiments that may be included within the invention as
defined by the appended claims.
[0016] I. Definitions
[0017] Unless stated other vise, the following terms and phrases as
used herein are intended to have the following meanings:
[0018] The term "label" refers to a moiety that, when attached to
the compositions of the invention, render such compositions
detectable using known detection means, e.g., spectroscopic,
photochemical, radioactive, biochemical, immunochemical, enzymatic
or chemical means. Exemplary labels include but are not limited to
fluorophores, chromophores, radioisotopes, spin labels, enzyme
labels and chemiluminescent labels. Such labels allow direct
detection of labeled compounds by a suitable detector, e.g., a
fluorescence detector. In addition, such labels include components
of multi-component labeling schemes, e.g., a system in which a
ligand binds specifically and with high affinity to a detectable
anti-ligand, e.g., a labeled antibody binds to its corresponding
antigen.
[0019] The term "hybridization enhancer" means moieties that serve
to enhance, stabilize, or otherwise positively influence
hybridization between two polynucleotides, e.g. intercalators
(e.g., U.S. Pat. No. 4,835,263), minor-groove binders (e.g., U.S.
Pat. No. 5,801,155), and cross-linking functional groups.
[0020] "Linking group" means a moiety capable of reacting with a
"complementary functionality" to form a "linkage." A linking group
and its associated complementary functionality is referred to
herein as a "linkage pair." Preferred linkage pairs include a first
member selected from the group isothiocyanate, sulfonyl chloride,
4,6-dichlorotriazinyl, succinimidyl ester, or other active
carboxylate, and a second member that is amine. Preferably a first
member of a linkage pair is maleimide, halo acetyl, or
iodoacetamide whenever the second member of the linkage pair is
sulfhydryl. (e.g., R. Haugland, Molecular Probes Handbook of
Fluorescent Probes and Research Chemicals, Molecular probes, Inc.
(1992)). In a particularly preferred embodiment, the first member
of a linkage pair is N-hydroxysuccinimidyl (NHS) ester and the
second member of the linkage pair is amine, where, to form an NHS
ester, a carboxylate moiety is reacted with
dicyclohexylcarbodiimide and N-hydroxysuccinimide.
[0021] The term "Watson/Crick base-pairing" refers to a pattern of
specific pairs of nucleotides, and analogs thereof, that bind
together through sequence-specific hydrogen-bonds, e.g. A pairs
with T and U, and G pairs with C.
[0022] The term "nucleoside" refers to a compound comprising a
purine, deazapurine, or pyrimidine nucleobase, e.g., adenine,
guanine, cytosine, uracil, thymine, 7-deazaadenine,
7-deazaguanosine, and the like, that is linked to a pentose at the
1'-position. When the nucleoside base is purine or 7-deazapurine,
the pentose is attached to the nucleobase at the 9-position of the
purine or deazapurine, and when the nucleobase is pyrimidine, the
pentose is attached to the nucleobase at the 1-position of the
pyrimidine, (e.g., Komberg and Baker, DNA Replication, 2nd Ed.
(Freeman, San Francisco, 1992)). The term "nucleotide" as used
herein refers to a phosphate ester of a nucleoside, e.g., a
triphosphate ester, wherein the most common site of esterification
is the hydroxyl group attached to the C-5 position of the pentose.
The term "nucleoside/tide" as used herein refers to a set of
compounds including both nucleosides and nucleotides.
[0023] The term "polynucleotide" means polymers of nucleotide
monomers, including analogs of such polymers, including double and
single stranded deoxyribonucleotides, ribonucleotides,
.alpha.-anomeric forms thereof, and the like. Monomers are linked
by "internucleotide linkages," e.g., phosphodiester linkages, where
as used herein, the term "phosphodiester linkage" refers to
phosphodiester bonds or bonds including phosphate analogs thereof,
including associated counterions, e.g., H.sup.+, NH.sub.4.sup.+,
Na.sup.+, if such counterions are present. Whenever a
polynucleotide is represented by a sequence of letters, such as
"ATGCCTG," it will be understood that the nucleotides are in 5' to
3' order from left to right and that "A" denotes deoxyadenosine,
"C" denotes deoxycytidine, "G" denotes deoxyguanosine, and "T"
denotes deoxythymidine, unless otherwise noted.
[0024] "Analogs" in reference to nucleosides/tides and/or
polynucleotides comprise synthetic analogs having modified
nucleobase portions, modified pentose portions and/or modified
phosphate portions, and, in the case of polynucleotides, modified
internucleotide linkages, as described generally elsewhere (e.g.,
Scheit, Nucleotide Analogs (John Wiley, New York, (1980); Englisch,
Angew. Chem. Int. Ed. Engl. 30:613-29 (1991); Agrawal, Protocols
for Polynucleotides and Analogs, Humana Press (1994)). Generally,
modified phosphate portions comprise analogs of phosphate wherein
the phosphorous atom is in the +5 oxidation state and one or more
of the oxygen atoms is replaced with a non-oxygen moiety, e.g.,
sulfur. Exemplary phosphate analogs include but are not limited to
phosphorothioate, phosphorodithioate, phosphoroselenoate,
phosphorodiselenoate, phosphoroanilothioate. phosphoranilidate,
phosphoramidate, boronophosphates, including associated
counterions, e.g., H.sup.+, NH.sub.4.sup.+, Na.sup.+, if such
counterions are present. Exemplary modified nucleobase portions
include but are not limited to 2,6-diaminopurine, hypoxanthine,
pseudouridine, C-5-propyne, isocytosine, isoguanine,
2-thiopyrimidine, and other like analogs. Particularly preferred
nucleobase analogs are iso-C and iso-G nucleobase analogs available
from Sulfonics. Inc., Alachua, Fla. (e.g., Benner, et al., U.S.
Pat. No. 5,432,272). Exemplary modified pentose portions include
but are not limited to 2'- or 3'-modifications where the 2'- or
3'-position is hydrogen, hydroxy, alkoxy, e.g., methoxy, ethoxy,
allyloxy, isopropoxy, butoxy, isobutoxy and phenoxy, azido, amino
or alkylamino, fluoro, chloro, bromo and the like. Modified
internucleotide linkages include phosphate analogs, analogs having
achiral and uncharged intersubunit linkages (e.g., Sterchak, E.P.,
et al., Organic Chem, 52:4202 (1987)), and uncharged
morpholino-based polymers having achiral intersubunit linkages
(e.g., U.S. Pat. No. 5,034,506). A particularly preferred class of
polynucleotide analogs where a conventional sugar and
internucleotide linkage has been replaced with a
2-aminoethylglycine amide backbone polymer is peptide nucleic acid
(PNA) (e.g., Nielsen et al., Science, 254: 1497-1500 (1991); Egholm
et al., J. Am. Chem. Soc., 114: 1895-1897 (1992)).
[0025] As used herein the term "primer-extension reagent" means a
reagent comprising components necessary to effect an enzymatic
template-mediated extension of a polynucleotide primer. Primer
extension reagents include (1) a polymerase enzyme, e.g., a
thermostable DNA polymerase enzyme such as Taq polymerase; (2) a
buffer; (3) one or more chain-extension nucleotides, e.g.,
deoxynucleotide triphosphates, e.g., deoxyguanosine
5'-triphosphate, 7-deazadeoxyguanosine 5'-triphosphate,
deoxyadenosine 5'-triphosphate, deoxythymidine 5'-triphosphate,
deoxycytidine 5'-triphosphate; and, optionally in the case of
Sanger-type DNA sequencing reactions, (4) one or more
chain-terminating nucleotides, e.g., dideoxynucleotide
triphosphates, e.g., dideoxyguanosine 5'-triphosphate,
7-deazadideoxyguanosine 5'-triphosphate, dideoxyadenosine
5'-triphosphate, dideoxythymidine 5'-triphosphate, and
dideoxycytidine 5'-triphosphate.
[0026] "Mobility-dependent analysis technique" means an analysis
technique based on differential rates of migration between
different analyte species. Exemplary mobility-dependent analysis
techniques include electrophoresis, chromatography, sedimentation,
e.g., gradient centrifugation, field-flow fractionation,
multi-stage extraction techniques and the like.
[0027] II. Target Nucleic Acid Sequence
[0028] A target nucleic acid sequence for use with the present
invention may be derived from any living, or once living, organism,
including but not limited to prokaryote, eukaryote, plant, animal,
and virus. The target nucleic acid sequence may originate from a
nucleus of a cell, e.g., genomic DNA, or may be extranuclear
nucleic acid, e.g., plasmid, mitrochondrial nucleic acid, various
RNAs, and the like. The target nucleic acid sequence may be first
reverse-transcribed into cDNA if the target nucleic acid is RNA.
Furthermore, the target nucleic acid sequence may be present in a
double stranded or single stranded form.
[0029] A variety of methods are available for obtaining a target
nucleic acid sequence for use with the compositions and methods of
the present invention. When the target nucleic acid sequence is
obtained through isolation from a biological matrix, preferred
isolation techniques include (1) organic extraction followed by
ethanol precipitation, e.g., using a phenol/chloroform organic
reagent (e.g., Ausubel et al. eds., Current Protocols in Molecular
Biology Volume 1, Chapter 2, Section I, John Wiley & Sons, New
York (1993)), preferably using an automated DNA extractor, e.g.,
the Model 341 DNA Extractor available from PE Applied Biosystems
(Foster City, Calif.); (2) stationary phase adsorption methods
(e.g., Boom et al., U.S. Pat. No. 5,234,809; Walsh et al.,
Biotechniques 10(4): 506-513 (1991)); and (3) salt-induced DNA
precipitation methods (e.g., Miller et al., Nucleic Acids Research,
16(3): 9-10 (1988)), such precipitation methods being typically
referred to as "salting-out" methods. Optimally, each of the above
isolation methods is preceded by an enzyme digestion step to help
eliminate unwanted protein from the sample, e.g., digestion with
proteinase K, or other like proteases.
[0030] To increase the sensitivity and specificity of the method of
the invention, preferably the target nucleic acid sequence is
amplified prior to performing the method using a suitable nucleic
acid amplification procedure. Such amplification may be linear or
non-linear, e.g., exponential. Exemplary amplification procedures
include, but are not limited to, the polymerase chain reaction
(PCR) (e.g., Mullis et al., U.S. Pat. Nos. 4,683,195, 4,683,195,
and 4,683,202), the self-sustained sequence replication reaction
(3SR) (e.g., Gingeras et al., Ann. Biol. Clin., 48: 498-501
(1990)), the ligation amplification reaction (LAR) (Wu and Wallace,
Genomics, 4: 560-569 (1989)), the ligase chain reaction (LCR)
(e.g., Winn-Deen, E., et al., Clin. Chem., 37: 1522 (1991)), and
the nucleic acid sequence based amplification reaction (NASBA)
(e.g., van Gemen et al., J. Virol. Methods, 43: 177-188 (1993)). In
a particularly preferred embodiment, amplification of the target
nucleic acid sequence is accomplished using PCR. Generally, the PCR
consists of an initial denaturation step that separates the strands
of a double stranded nucleic acid, followed by the repetition of
(1) an annealing step, which allows two amplification primers to
anneal specifically to positions flanking a target nucleic acid
sequence; (2) an extension step which extends the primers in a
5'.fwdarw.3' direction thereby forming an amplicon nucleic acid
complementary to a portion of the target nucleic acid sequence
located between the primers, and (3) a denaturation step which
causes the separation of the amplicon. Each of the above steps may
be conducted at a different temperature, where the temperature
changes may be effected using an automated thermocycler (e.g., PE
Applied Biosystems, Foster City, Calif.). In a particularly
preferred embodiment, multiple loci of the target nucleic acid
sequence are amplified by multiplex PCR, thereby allowing multiple
regions of a target nucleic acid sequence to be investigated
simultaneously (e.g., Chamberlain et al., Nucleic Acids Research,
16: 11141-11156 (1988); PCR Primer: A Laboratory Manual,
Dieffenbach and Dveksler, eds., CSHL Press (1995); Caskey et al.,
U.S. Pat. No. 5,582,989).
[0031] III. Binary Compositions
[0032] This section describes several preferred embodiments of
binary compositions designed for use in the methods of the present
invention. In a typical case, the binary compositions are part of a
composition containing a plurality of probes and associated
mobility modifiers for use in detecting a plurality of target
nucleic acid sequences, according to a variety of methods, several
of which are described herein.
[0033] As shown schematically in FIGS. 1, 2 and 3, the binary
composition of the present invention comprises (1) a probe 5
comprising a target-specific portion 10 for sequence-specific
hybridization to a target nucleic acid sequence, and a tag portion
15, and (2) a mobility-modifier 50 comprising a tag complement 55
for binding to the tag portion 15 of the probe, and a tail 60 for
effecting a particular mobility in a mobility-dependent analysis
technique. According to an important feature of the invention, when
a probe 5 and a mobility-modifier 50 having complementary tag 15
and tag complement 55 portions are contacted, a stable
probe/mobility-modifier complex 80 is formed.
[0034] As stated above, the probe 5 of the binary composition
includes a target-specific portion 10 for sequence-specific
hybridization to a target nucleic acid sequence, and a tag portion
15 for binding to a tag complement 55 of a mobility modifier
50.
[0035] The target-specific portion 10 of the probe may be any
entity capable of sequence-specific binding to a target nucleic
acid sequence, either in a double stranded or single stranded form,
where, preferably, such sequence-specific binding is able to
discriminate between target nucleic acid sequences differing by as
little as a single nucleotide, or nucleotide equivalent. Generally,
the term "hybridization" or "annealing" will be used to describe
such sequence-specific binding between a probe and a target nucleic
acid sequence. Target-specific portions may be designed for
sequence specific binding to a single-stranded target nucleic acid
sequence through Watson-Crick base pairing, or sequence-specific
binding to a double-stranded target nucleic acid sequence through
Hoogstien binding sites in a major groove of a duplex nucleic acid
(e.g., Kornberg, A., et al., DNA Replication, pp 46-47, W.H.
Freeman and Co., New York (1992)), or any other sequence-specific
binding or hybridization mechanism. Preferably, the target-specific
portion of a probe will interact with a number of nucleotides in a
target nucleic acid sequence large enough to unambiguously identify
a unique target nucleic acid sequence, while at the same time small
enough to maintain an ability to discriminate between target
nucleic acid sequences differing by as little as a single
nucleotide.
[0036] Preferred target-specific portions include but are not
limited to antibodies having specificity for a particular nucleic
acid sequence, small-molecule synthetic ligands having nucleic acid
sequence-recognition properties (e.g., White et al., Nature, 391:
468-471 (1998); Kielkopf et al., Nat. Struct. Biol., 5(2): 104-109;
Becker et al., J. Am. Chem. Soc., 101(13): 3664-6 (1979)),
polynucleotides, and the like, including combinations of such
structures.
[0037] Particularly preferred target-specific portions comprise
polynucleotides. Typically, when a target-specific portion of a
probe is a polynucleotide, the target-specific portion will have a
size such that it interacts with about 10 to 40 nucleotides of a
target nucleic acid sequence, more preferably about 15 to 30
nucleotides. In certain circumstances, in order to facilitate
polymerase-mediated extension of the probe, the target-specific
portion includes a 3'-end having an --OH group or other moiety that
allows polymerase-mediated incorporation of a nucleotide onto the
3'-end of the probe, or allows enzymatic or chemical ligation of
the probe to a neighboring polynucleotide.
[0038] A particularly preferred polynucleotide analog, suitable as
a target-specific portion of a probe (as well as other portions of
the binary compositions) is PNA. PNA is preferred because it offers
Watson-Crick target-sequence specificity, strong target-probe
affinity, e.g., a high melting temperature relative to
similarly-sized conventional phosphodiester polynucleotide, the
ability to bind a target nucleic acid sequence in both duplex and
triplex configurations, and the ability to bind to a target nucleic
acid sequence in both a parallel- and anti-parallel orientation
(e.g., co-pending U.S. patent application titled "Binary Probe and
Clamp Composition and Methods for Target Hybridization Detection,"
by K. Livak, M. Egholm and M. Hunkapiller, filed Jan. 15,
1999).
[0039] The tag portion 15 of a probe 5 of the present invention may
be any entity capable of binding to, and forming a complex with, a
tag-complement portion 55 of a mobility modifier 50. Additionally,
preferred tag and tag-complements should form a complex that (1) is
stable under conditions typically used in nucleic acid analysis
methods, e.g., aqueous, buffered solutions at room temperature; (2)
is stable under mild nucleic-acid denaturing conditions; and (3)
does not adversely effect a sequence specific binding of a
target-specific portion of a probe with a target nucleic acid
sequence. In addition, tags and tag complements of the invention
should accommodate sets of distinguishable tags and tag complements
such that a plurality of different probes and associated mobility
modifiers may be present in the same reaction volume without
causing cross-interactions among the tags, tag complements, target
nucleic acid sequence and target-specific portions of the probes.
Methods for selecting sets of tag sequences that minimally cross
hybridize are described elsewhere (e.g., Brenner and Albrecht, PCT
Patent Application No. WO 96/41011).
[0040] Exemplary tags and/or tag complements include but are not
limited to antibodies and associated antigen or hapten, receptors
and associated ligands, avidin (or streptavidin) and biotin, and
polynucleotide sequences and their complementary sequences.
[0041] In a preferred embodiment, the tag and tag complement are
each polynucleotide. In a preferred polynucleotide tag or tag
complement, the tags and complements are rendered non-extendable by
a polymerase, e.g., by including sugar modifications such as a
3'-phosphate, a 3'-acetyl, a 2'-3'-dideoxy, a 3'-amino, and a 2'-3'
dehydro.
[0042] A particularly preferred polynucleotide tag and tag
complement pair comprises a tag that is a conventional synthetic
polynucleotide, and a tag complement that is PNA. Where the PNA tag
complement has been designed to form a triplex structure with a
tag, the tag complement may include a "hinge" region in order to
facilitate triplex binding between the tag and tag complement. In a
more preferred embodiment, tag and tag complement is sequences
comprise repeating sequences. Such repeating sequences in the tag
and tag complement are preferred by virtue of their (1) high
binding affinity, (2) high binding specificity, and (3) high
solubility. A particularly preferred repeating sequence for use as
a duplex-forming tag or tag complement is (CAG).sub.n, where the
three base sequence is repeated from about 1 to 10 times (e.g.,
Boffa, et al., PNAS (USA), 92:1901-05 (1995); Wittung, et al.,
Biochemistry, 36:7973-79 (1997)). A particularly preferred
repeating sequence for use as a triplex-forming tag or tag
complement is (TCC).sub.n.
[0043] PNA and PNA/DNA chimera molecules can be synthesized using
well known methods on commercially available, automated
synthesizers, with commercially available reagents (e.g., Dueholm,
et al., J. Org. Chem., 59:5767-73 (1994); Vinayak, et al.,
Nucleosides & Nucleotides, 16:1653-56 (1997)).
[0044] When a tag portion is a polynucleotide, the tag may comprise
all, part, or none of the target-specific portion of the probe. In
some embodiments of the invention, the tag may consist of some or
all of the target-specific portion of the probe. In other
embodiments of the invention, the tag does not comprise any portion
of the target-specific portion of the probe.
[0045] Tags 15 may be attached to target-specific portions 10 of
probes using any chemically stable linkage, where the choice of
linkage chemistry will depend on the nature of the tag and
target-specific portions of the probe. In one preferred embodiment,
the linkage is formed by the reaction of a primary or secondary
amino moiety with a "complementary functionality." Preferably, the
complementary functionality is isothiocyanate, isocyanate, acyl
azide, N-hydroxysuccinimide (NHS) ester, sulfonyl chloride,
aldehyde or glyoxal, epoxide, carbonate, aryl halide, imidoester,
carbodiimide, anhydride, 4,6-dichlorotriazinylamine, or other
active carboxylate (e.g., Hermanson, Bioconjugate Techniques,
Academic Press (1996)). In a particularly preferred embodiment, the
complementary functionality is an activated NHS ester which reacts
with the amine of the substituted propargylethoxyamido nucleoside
of the invention, where to form the activated NHS ester, a
carboxylate complementary functionality is reacted with
dicyclohexylcarbodiimide and N-hydroxysuccinimide to form the NHS
ester (Khanna, et al., U.S. Pat. No. 4,318,846 (1988); Kasai, et
al., Anal. Chem., 47: 34037 (1975)).
[0046] One particularly preferred linkage well suited for the case
where both a target specific portion and a tag of a probe are
polynucleotide comprised incorporating 1,3-propanediol or
1,4-anhydro-2-deoxy-D-ribotol subunits between the tag and target
complementary portions of the probe (e.g., Gade et al., GATA,
10(2): 61-65 (1993); Ugozzoli et al., GATA, 9: 107-112 (1992)). In
another preferred embodiment in which both the target-specific
portion and the tag portion of a probe are polynucleotide, the
target-specific portion and the tag portion are linked through
internucleotide linkages making up the polynucleotide itself.
[0047] The mobility modifier 50 of the binary composition of the
present invention comprises a tag complement 55 portion for binding
to the tag portion 15 of the probe, and a tail 60 for effecting a
particular mobility in a mobility-dependent analysis technique.
[0048] The tail portion of a mobility modifier may be any entity
capable of effecting a particular mobility of a
probe/mobility-modifier complex 80 in a mobility-dependent analysis
technique. Preferably, the tail portion 60 of the mobility modifier
50 of the invention should (1) have a low polydispersicy in order
to effect a well-defined and easily resolved mobility, e.g., Mw/Mn
less than 1.05; (2) be soluble in an aqueous medium; (3) not
adversely affect probe-target hybridization or tag-tag complement
binding; and (4) be available in sets such that members of
different sets impart distinguishable mobilities to their
associated probe/mobility-modifier complexes.
[0049] In a particularly preferred embodiment of the present
invention, the tail portion of the mobility modifier comprises a
polymer. Specifically, the polymer forming the tail may be
homopolymer, random copolymer, or block copolymer. Furthermore, the
polymer may have a linear, comb, branched, or dendritic
architecture. In addition, although the invention is described
herein with respect to a single polymer chain attached to an
associated mobility modifier at a single point, the invention also
contemplates mobility modifiers comprising more than one polymer
chain element, where the elements collectively form a tail
portion.
[0050] Preferred polymers for use in the present invention are
hydrophilic, or at least sufficiently hydrophilic when bound to a
tag complement to ensure that the tag complement is readily soluble
in aqueous medium. The polymer should also not affect the
hybridization between a target nucleic acid sequence and the
target-specific portion of a probe associated with the mobility
modifier. Where the probe is charged, as in the case of a
polynucleotide probe, and the mobility-dependent analysis technique
is electrophoresis, the polymers are preferably uncharged or have a
charge/subunit density which is substantially less than that of the
probe.
[0051] In one preferred embodiment, the polymer is polyethylene
oxide (PEO), e.g., formed from one or more hexaethylene oxide (HEO)
units, where the HEO units are joined end-to-end to form an
unbroken chain of ethylene oxide subunits. Other exemplary
embodiments include a chain composed of N 12 mer PEO units, and a
chain composed of N tetrapeptide units, where N is an adjustable
integer (e.g., Grossman et al., U.S. Pat. No. 5,777,096).
[0052] Clearly, the synthesis of polymers useful as tail portions
of a mobility modifier of the present invention will depend on the
nature of the polymer. Methods for preparing suitable polymers
generally follow well known polymer subunit synthesis methods.
Methods of forming selected-length PEO chains are discussed below.
These methods, which involve coupling of defined-size,
multi-subunit polymer units to one another, either directly or
through charged or uncharged linking groups, are generally
applicable to a wide variety of polymers, such as polyethylene
oxide, polyglycolic acid, polylactic acid, polyurethane polymers,
polypeptides, and oligosaccharides. Such methods of polymer unit
coupling are also suitable for synthesizing selected-length
copolymers, e.g., copolymers of polyethylene oxide units
alternating with polypropylene units. Polypeptides of selected
lengths and amino acid composition, either homopolymer or mixed
polymer, can be synthesized by standard solid-phase methods (e.g.,
Fields and Noble, Int. J. Peptide Protein Res., 35: 161-214
(1990)).
[0053] In one preferred method for preparing PEO polymer chains
having a selected number of HEO units, an HEO unit is protected at
one end with dimethoxytrityl (DMT), and activated at its other end
with methane sulfonate. The activated HEO is then reacted with a
second DMT-protected HEO group to form a DMT-protected HEO dimer.
This unit-addition is then carried out successively until a desired
PEO chain length is achieved (e.g., Levenson et al., U.S. Pat. No.
4,914,210).
[0054] Another particularly preferred polymer for use as a tail
portion is PNA. The advantages, properties and synthesis of PNA
have been described above. In particular, when used in the context
of a mobility-dependent analysis technique comprising an
electrophoretic separation in free solution, PNA has the
advantageous property of being essentially uncharged.
[0055] Coupling of the polymer tails to a polynucleotide tag
complement can be carried out by an extension of conventional
phosphoramidite polynucleotide synthesis methods, or by other
standard coupling methods, e.g., a bis-urethane tolyl-linked
polymer chain may be linked to an polynucleotide on a solid support
via a phosphoramidite coupling. Alternatively, the polymer chain
can be built up on a polynucleotide (or other tag portion) by
stepwise addition of polymer-chain units to the polynucleotide,
e.g., using standard solid-phase polymer synthesis methods.
[0056] As noted above, the tail portion 60 of the mobility modifier
imparts a mobility to a probe/mobility modifier complex that is
distinctive for each different probe/mobility modifier complex. The
contribution of the tail to the mobility of the complex will in
general depend on the size of the tail. However, addition of
charged groups to the tail, e.g., charged linking groups in the PEO
chain, or charged amino acids in a polypeptide chain, can also be
used to achieve selected mobility characteristics in the
probe/mobility modifier complex. It will also be appreciated that
the mobility of a probe/mobility modifier complex may be influenced
by the properties of the probe itself, e.g. in electrophoresis in a
sieving medium, a larger probe will reduce the electrophoretic
mobility of the probe/mobility modifier complex.
[0057] The tag complement portion 55 of a mobility modifier 50
according to the present invention may be any entity capable of
binding to, and forming a complex with, a tag portion 15 of a probe
5. The structure and properties of the tag complement are
essentially the same as those discussed above with respect to the
tag portion 15 of the probe 5. Furthermore, the tag-complement
portion of the mobility modifier may be attached to the tail
portion using conventional means substantially as described above
with respect to the attachment of the tag to the probe.
[0058] When a tag complement is a polynucleotide, e.g., PNA, the
tag complement may comprise all, part, or none of the tail portion
of the mobility modifier. In some embodiments of the invention, the
tag complement may consist of some or all of the tail portion of
the mobility modifier. In other embodiments of the invention, the
tag complement does not comprise any portion of the tail portion of
the mobility modifier. For example, because PNA is uncharged,
particularly when using free solution electrophoresis as the
mobility-dependent analysis technique, the same PNA oligomer may
act as both a tag complement and a tail portion of a mobility
modifier.
[0059] In a preferred embodiment of the binary composition
according to the present invention, a member of the binary
composition includes a hybridization enhancer. In certain
circumstances, using a hybridization enhancer allows for shorter
target-specific portions to be used, thereby increasing the
sensitivity of a probe to single-base mismatches between the probe
and target nucleic acid sequence. The hybridization enhancer may be
attached to any portion of a probe or mobility modifier, so long as
it is attached to the probe or mobility modifier is such a way as
to allow interaction with a target-probe duplex. However,
preferably, the hybridization enhancer is covalently attached to a
probe of the binary composition. A particularly preferred
hybridization enhancer for use in the present invention is
minor-groove binder, e.g., netropsin, distamycin, and the like.
[0060] In another preferred embodiment, a member of the binary
composition includes a label. Labels may be attached using well
known techniques (e.g., Hermanson, Bioconjugate Techniques,
Academic Press (1996)). Particularly preferred labels include
fluorescent dyes.
[0061] III. Sequence Detection Methods
[0062] The practice of the methods of the present invention will
utilize, unless otherwise indicated, standard techniques of
molecular biology, which are within the skill of the art.
[0063] In one aspect, the present invention provides a method for
detecting one or more target nucleic acid sequences present in a
sample. The method is generally performed as follows. A sample
potentially containing one or more target nucleic acid sequences is
contacted with a probe comprising a target-specific portion for
sequence-specific binding to the target nucleic acid sequence and a
tag, under conditions suitable for sequence-dependent binding of
the probe and the target nucleic acid sequence, e.g., Watson-Crick
or Hoogstien binding. A mobility modifier comprising a tag
complement for binding to the tag is contacted with the probe,
under conditions suitable for binding the tag to the tag
complement, thereby forming a probe/mobility modifier complex. The
probe/mobility modifier complex is then treated to form a modified
probe, e.g., a labeled nucleotide terminator is enzymatically added
to a 3'-end of the probe thereby extending the probe by one
nucleotide and labeling the probe. Finally, the probe/mobility
modifier complex is analyzed using a mobility-dependent analysis
technique. Clearly, it will be understood by one of ordinary skill
in the molecular biology art that the order of the steps of the
method is not critical to the invention, e.g., the probe may be
treated before or after the probe/mobility modifier complex is
formed.
[0064] The conditions necessary to effect sequence-specific
probe-target binding depend upon the nature of the target-specific
portion of the probe, and the nature of the target nucleic acid
sequence, e.g., is the target nucleic acid sequence in a single- or
double-stranded form. Preferably, conditions are chosen such that
single nucleotide variations in the target nucleic acid sequences
are detectable. Generally, conditions should be chosen to obtain a
balance between specificity of probe annealing, i.e., the frequency
with which an undesired nucleic acid sequence participates in a
binding event with the probe, and efficiency of binding, i.e., the
extent to which a desired target nucleic acid sequence participates
in a binding reaction with a probe.
[0065] When the target-specific portion of a probe is a
polynucleotide, specificity of probe annealing is generally
controlled by the length of the target-specific portion of the
probe, the solvent conditions, e.g., salt concentration, and the
temperature of the annealing, or hybridization, reaction.
Typically, polynucteotides between about 10 and 30 nucleotides are
preferred because such polynucleotides tend to be very sequence
specific when the annealing temperature is set within a few degrees
of a probe melting temperature (e.g., Dieffenbach et al., PCR
Primer: A Laboratory Manual, Dieffenbach and Dveksler, eds., p
133-142, CSHL Press, New York (1995)). Other factors that will
influence the characteristics of the hybridization interaction
include the GC content of the probe and target sequence and the
presence of hybridization enhancers. A number of computer programs
are available to facilitate selection of target-specific portions
of probes in different contexts (e.g., Osborne, CABIOS, 8: 83
(1991); Montpetit et al., J. Virol. Methods, 36: 119-128
(1992)).
[0066] Following probe binding to the target nucleic acid sequence,
e.g., by polynucleotide hybridization, the probes may be treated to
selectively modify probes that have bound to the target nucleic
acid sequences in a sequence-specific manner. Such selective
modification serves to indicate when and where a target specific
binding event has occurred, and may serve to provide additional
information regarding the tar-et nucleic acid sequence beyond that
gleaned from simple probe hybridization. Several alternative
modification methods are available depending on the nature of the
probe (e.g., Grossman et al., U.S. Pat. No. 5,777,096).
[0067] In one preferred modification method, a polynucleotide probe
is joined by ligation to a second polynucleotide, e.g., by
chemical, photo-chemical or enzymatic ligation (e.g., Landegren et
al., Science, 241: 1077-1030 (1988); Whiteley, U.S. Pat. No.
5,521,065; Baron et al., Nature Biotechnology, 14: 1279-1282
(1996); Barany, Proc. Natl. Acad. Sci. USA, 88: 189-193 (1991)). In
a particularly preferred embodiment of this ligation modification
step, the ligation junction is located across an expected
single-base polymorphism, e.g, a single-base mutation site. In
another preferred embodiment, the second polynucleotide includes a
label such that only probes that have been ligated to a second
polynucleotide become labeled. Signal amplification can be achieved
by thermocycling the ligation reaction, e.g., a LAR reaction.
[0068] In another preferred modification method, one or more probes
are extended in a polymerase-mediated primer extension reaction in
the presence of a primer extension reagent (e.g., Mullis, U.S. Pat.
No. 4,683,202; Sanger and Coulson, Proc. Natl. Acad. Sci. USA, 74:
5463-5467 (1977)). In a particularly preferred version of this
embodiment, known generally as minisequencing, or single nucleotide
extension (SNE), the primer extension reagent does not contain any
chain-extension nucleotides, but rather contains one or more
chain-terminating nucleotides, e.g., dideoxynucleotide terminators
(e.g., Syvanen et al., Genomics, 8: 684-692 (1990); Soderlund and
Syvanen, PCT Patent Application No. WO 91/13075; Goelet et al., PCT
Patent Application No. WO 92/15712) Thus, the probes are extended
by only a single nucleotide, and the identity of that nucleotide
provides information about the target sequence immediately adjacent
to the 3'-end of the probe. More preferably, the chain-terminating
nucleotide is labeled with a label capable of determining the
identity of the nucleotide, e.g., whether the nucleotide is an A,
G, C or T nucleotide, e.g., by attaching a fluorescent label to the
nucleotide.
[0069] In yet another preferred modification method, the probe is
modified by the enzymatic cleavage, e.g., cleavage by RNaseH
endonuclease, and/or activation of a cleavable probe bound to a
target region (e.g., Duck et al., Biotechniques, 9(2): 147-152
(1990); Duck et al., U.S. Pat. No. 5,011,769; U.S. Pat. No.
5,792,607).
[0070] To effect formation of a probe/mobility modifier complex,
the probe and the mobility modifier are contacted under conditions
such that the tag portion of the probe and the tag complement
portion of the mobility modifier bind in a specific manner to form
a stable complex. Methods and conditions used to effect the
formation of the probe/mobility modifier complex will depend on the
nature of the tag and tag complement portions of the probe and
mobility modifier as described above. In a particularly preferred
embodiment of the present invention, the tag is a conventional
polynucleotide and the tag complement is PNA, where the PNA binds
to the polynucleotide tag in a duplex or triplex configuration, and
the binding conditions are chosen such that the PNA and
conventional polynucleotide form a stable and sequence-specific
bond (e.g., Perry-O'Keefe et al., Proc. Natl. Acad. Sci USA, (93:
14670-14675 (1996)).
[0071] In another preferred embodiment, both the tag and tag
complement are conventional polynucleotide, and after formation of
the probe/mobility modifier complex, the duplex formed by the tag-
and tag complement is cross-linked using conventional chemical or
photochemical nucleic acid crosslinking techniques (e.g., Meyer et
al., J. Amer. Chem. Soc., 111:8517-19 (1989); Pieles et al.,
Nucleic Acids Res., 13:2399-2412 (1989); Praseuth et al., Proc.
Natl. Acad. Sci. USA, 85:1349-53 (1988)). To avoid crosslinking the
probe to the target nucleic acid, the tag/tag complement
crosslinking reaction is preferably performed when the probe and
target are not hybridized to one another.
[0072] In a particularly preferred embodiment of the invention, a
plurality of probes is directed against a plurality of target
nucleic acid sequences, where each probe includes a unique tag
portion, specific for a tag complement portion of a particular
mobility modifier. A plurality of mobility modifiers may be
contacted with the probes, where each mobility modifier includes a
tag complement directed towards a particular tag. Therefore, a
plurality of probe/mobility modifier complexes are formed in a
single step.
[0073] According to an important feature of the invention, a
plurality of probe/mobility modifier complexes are resolved via a
mobility-dependent analysis technique. One advantage of this
feature is that probes used in the method can be designed to have
similar sizes and therefore exhibit substantially the same
hybridization kinetics, while being easily resolved in a
mobility-dependent analysis technique.
[0074] In one embodiment of the invention, probes are resolved
(separated) by liquid chromatography. Exemplary stationary phase
media for use in the method include reversed-phase media (e.g.,
C-18 or C-8 solid phases), ion-exchange media (particularly
anion-exchange media), and hydrophobic interaction media. In a
related embodiment, the probes can be separated by micellar
electrokinetic capillary chromatography (MECC).
[0075] Reversed-phase chromatography is carried out using an
isocratic, or more typically, a linear, curved, or stepped solvent
gradient, wherein the level of a nonpolar solvent such as
acetonitrile or isopropanol in aqueous solvent is increased during
a chromatographic run, causing analytes to elute sequentially
according to affinity of each analyte for the solid phase. For
separating polynucleotides, an ion-pairing agent (e.g., a
tetra-alkylammonium) is typically included in the solvent to mask
the charge of phosphate.
[0076] The mobility of a probe can be varied by attachment to
mobility modifiers comprising polymer chains that alter the
affinity of the probe for the solid, or stationary, phase. Thus,
with reversed phase chromatography, an increased affinity of the
probe for the stationary phase can be attained by addition of a
moderately hydrophobic tail (e.g., PEO-containing polymers, short
polypeptides, and the like) to the probe. Longer tails impart
greater affinity for the solid phase, and thus require higher
non-polar solvent concentration for the probe to be eluted (and a
longer elution time).
[0077] Generally, in anion-exchange chromatography, analytes are
eluted from a positively charged stationary phase using a salt
gradient, where analytes elute according to the number and
distribution of negative charges in each analyte. As polyanions,
polynucleotides elute according to the length of the
polynucleotide, with the smallest polynucleotides eluting first,
and longer polynucleotides eluting as the concentration of salt is
increased over time. Thus, where anion exchange chromatography is
used in the method of the invention, the mobility modifiers
attached to the probes may be charged; positively charged tails can
be used to reduce the affinity of a probe for the solid phase, and
negatively charged tails can be used to increase affinity for the
solid phase. Similar considerations apply to hydrophobic
interaction chromatography.
[0078] In micellar electrokinetic capillary chromatography (MECC),
polynucleotides may separate by electrophoretic passage through a
separation medium that contains micelles formed by surfactant
molecules (e.g., sodium dodecyl sulfate). Sample separation is
mediated by partitioning of the sample components between a primary
phase, formed by the running buffer, and a secondary phase, formed
by micelles, in a separation process that may be characterized as a
form of chromatography. For enhanced polynucleotide separation, the
separation medium may contain divalent metal ions, for complexing
with sample polynucleotides to modify polynucleotide
mobilities.
[0079] According to a particularly preferred embodiment of the
present invention, the probe/mobility modifier complexes are
resolved by electrophoresis in a sieving or non-sieving matrix.
Preferably, the electrophoretic separation is carried out in a
capillary tube by capillary electrophoresis (e.g., Capillary
Electrophoresis: Theory and Practice, Grossman and Colburn eds.,
Academic Press (1992)). Preferred sieving matrices which can be
used include covalently crosslinked matrices, such as
polyacrylamide covalently crosslinked with bis-acrylamide; gel
matrices formed with linear polymers (e.g., Madabhushi et al. U.S.
Pat. No. 5,552,028); and gel-free sieving media (e.g., Grossman et
al., U.S. Pat. No. 5,624,800; Hubert and Slater, Electrophoresis,
16: 2137-2142 (1995); Mayer et al., Analytical Chemistry, 66(10):
1777-1780 (1994)). The electrophoresis medium may contain a nucleic
acid denaturant, such as 7M formamide, for maintaining
polynucleotides in single stranded form. Suitable capillary
electrophoresis instrumentation are commercially available, e.g.,
the ABI PRISM.TM. Genetic Analyzer (PE Biosystems, Foster City,
Calif.).
[0080] To facilitate detection, an element of the binary
compositions of the invention may contain, or can be modified to
contain, a label which allows direct detection of a labeled element
by a suitable detector. Preferably, the label is a fluorescent
label which, more preferably, is spectrally resolvable from other
fluorescent labels in a set. For example, the reporter label may be
attached to the 5' or 3'-terminal base of the polynucleotide
portion of the probe, by methods well known in the nucleotide
chemistry art (e.g., Fung et al, U.S. Pat. No. 4,855,225; Prober et
al, Science 238, 4767-4771 (1987); Smith et al., Nucleic Acids Res.
13, 2399-2412 (1985)).
[0081] Exemplary fluorescent labels include the dyes 5- and
6-carboxyfluorescein, 5- and 6-carboxy-4,7-dichlorofluorescein,
2',7'-dimethoxy-5- and 6-carboxy-4,7-dichlorofluorescein,
2',7'-dimethoxy-4',5'-dichloro-5- and 6-carboxyfluorescein,
2',7'-dimethoxy-4',5'-dichloro-5- and
6-carboxy-4,7-dichlorofluorescein, 1',2',7',8'-dibenzo-5- and
6-carboxy-4,7-dichlorofluorescein,
1',2',7',8'-dibenzo-4',5'-dichloro-5- and
6-carboxy-4,7-dichlorofluoresce- in, 2',7'-dichloro-5- and
6'-carboxy-4,7-dichlorofluorescein, and 2',4',5',7'-tetrachloro-5-
and 6-carboxy-4,7-dichlorofluorescein. The above-mentioned dyes are
disclosed elsewhere (e.g., Hobbs, Jr., U.S. Pat. No. 4,997,928;
Fung et al, U.S. Pat. No. 4,855,225; and Menchen et al, U.S. Pat.
No. 5,188,934) Alternatively, probes of the invention may be
labeled with spectrally resolvable rhodamine dyes (e.g., Bergot et
al, U.S. Pat. No. 5,366,860). A particularly preferred class of
dyes useful in the present invention comprise fluorescent energy
transfer dyes (e.g., Lee et at., U.S. Pat. No. 5,800,996; Lee et
al., Nucleic Acids Research, 25 (14): 2816-2822 (1997)).
[0082] An exemplary preferred embodiment of a method according to
the present invention is schematically depicted in FIGS. 4A, 4B, 4C
and 4D. In FIG. 4A, four polynucleotide probes 105, 110, 115 and
120 are hybridized to a target nucleic acid sequence 100 in a
single reaction mixture under conditions suitable for
sequence-specific hybridization. Next, in FIG. 4B, the hybridized,
or bound, probes are modified to form modified probes 125, 130, 135
and 140. For example, the modification step may comprise a
single-nucleotide primer extension reaction, i.e., a
mini-sequencing reaction, in which the added nucleotide terminator
is labeled with a distinguishable label, e.g., a
spectrally-resolvable fluorescent label, or a ligation reaction,
where the second polynucleotide contains a distinguishable label.
Next, in FIG. 4C, the modified probes 125, 130, 135 and 140 are
contacted with their associated mobility modifiers 150, 160, 170
and 180, respectively, to form probe/mobility modifier complexes
155, 165, 175 and 185, where each probe is associated with a
mobility modifier having a particular size that results in a
different mobility address for each probe/mobility modifier
complex. Finally, in FIG. 4D, the probe/mobility modifier complexes
155, 165, 175 and 185 are resolved using a mobility-dependent
analysis technique, e.g., capillary electrophoresis in a sieving or
non-sieving medium, resulting in an electropherogram including
peaks 190, 195, 200 and 205 corresponding to probe/mobility
modifier complexes 155, 165, 175 and 185, respectively.
[0083] In the above example, each probe was resolved to a separate
mobility address. However, it will be realized that, in order to
conserve mobility addresses, it may be desirable in some
circumstance to place several probes at the same mobility address,
and distinguish the probes within each address by a distinguishable
label, e.g., spectrally-resolvable fluorescent labels.
[0084] It will be appreciated that a particularly attractive
feature of the methods and binary compositions of the present
invention is that a single set of mobility modifiers can be used
with different sets of target-specific probes, thereby greatly
reducing the number of tailed entities that must be
synthesized.
[0085] In one exemplary system, 10,000 biallelic SNP loci are
interrogated using 100 mobility modifiers and 10,000 unlabeled and
untailed polynucleotide probes. The system comprises 100 different
mobility modifiers, each mobility modifier having a distinguishable
tag complement and a distinguishable mobility when part of a
probe/mobility modifier complex. The system further comprises 100
sets of probes, each set comprising 100 individual probes, where
each probe comprises a distinguishable tag portion, and each set of
probes is located in a separate reaction tube. An aliquot of a
sample containing a target nucleic acid comprising a possible
20,000 target nucleic acid sequences is added to each reaction tube
of the 100 tube collection of tubes, i.e., each of the two alleles
of the 10,000 loci. Using a multiplex PCR, each of the target
sequences is amplified. Then, in each tube, the probes and the
amplified target nucleic acids are contacted under conditions
effective for sequence-dependent hybridization. Next, the
hybridized probes are modified by conducting a minisequencing
reaction using fluorescently-labeled nucleotide terminator, where
each of the A, G, C and T terminators are labeled with a spectrally
resolvable fluorescent label. Next, to each of the 100 reaction
tubes is added the same collection of 100 mobility modifiers. Then,
each tube is separately analyzed using a mobility-dependent
analysis technique such that a color is associated with each
mobility address, e.g., each tube is simultaneously analyzed by
electrophoresis, using a multicapillary capillary electrophoresis
system, e.g., ABI PRISM.TM. Model 3700 Genetic Analyzer (PE
Biosystems, Foster City, Calif.). Note that in the context of the
present invention, a mobility address may be based on an absolute
value of an electrophoretic mobility or a relative electrophoretic
mobility based on an internal or external standard. Finally, the
resulting color-mobility address data are compared with a base-line
data set stored in a computer and a genotype of the sample is
determined. Thus, in this exemplary embodiment, while 100.times.100
(10,000) different probes are required, i.e., one probe for each
locus-specific target nucleic acid sequence, only 100 different
mobility modifiers are required. And, in an example such as this
where the modification step serves to label the probes and to
provide additional sequence information, i.e., the identity of a
nucleotide immediately adjacent to a probe's 3'-end, none of the
10,000 probes need to be labeled beforehand. Therefore, as this
example demonstrates, using the methods and compositions of the
present invention, to create an assay capable of interrogating
40,000 different target sequences, e.g., 10,000 SNP loci, one need
only to make 100 different mobility modifiers and 10,000 unlabeled
and untailed probes.
[0086] Of course, each of the above sets may be automated using a
computer-controlled X-Y-Z laboratory robot, e.g., the BioMek from
Beckman Instruments, used in combination with a high-throughput
capillary electrophoresis device, e.g., the ABI PRISM.TM. 3700 DNA
Analyzer from PE Biosystems.
[0087] All publications and patent applications are herein
incorporated by reference to the same extent as if each individual
publication or patent application was specifically, expressly and
individually indicated to be incorporated by reference when first
cited.
[0088] Although only a few embodiments have been described in
detail above, those having ordinary skill in the molecular biology
art will clearly understand that many modifications are possible in
the preferred embodiment without departing from the teachings and
spirit thereof. All such modifications are intended to be
encompassed within the following claims.
* * * * *